Vir Biotechnology shares are trading higher after HC Wainwright & Co maintained a Buy rating on the stock and raised its price target from $135 to $200.

Your email address will not be published. Required fields are marked *

Comment *

Name *

Email *

Website

Save my name, email, and website in this browser for the next time I comment.